GENOTYPE-PHENOTYPE ASSOCIATIONS PROVIDE A RATIONAL TO IDENTIFY POTENTIALLY ACTIONABLE VUS

Silvana Lobo  1     Rita Monteiro  1     Liliana Sousa  1     Hugo Pinheiro  1     Sergio Castedo  1     Fatima Carneiro  2     Luzia Garrido  3     Manuel Teixeira  4     Genevieve Michils  5     Vicent Bours  6     Robin de Putter  7     Lisa Golmard  8     Chrystelle Colas  8     Maud Blanluet  8     Camille Desseignés  9     Coulet Florence  9     Stefan Aretz  10     Isabel Spier  11     Robert Hüneburg  11     Guglielmina Ranzani  12     Maurizio Genuardi  13     Ana Patiño-García  14     Conxi Lázaro  15     Gabriel Capellà  15     Joan Brunet-Vidal  16     Judith Balmana  17     Elena Domínguez-Garrido  18     Marjolin Ligtenberg  19     Rebecca FitzGerald  20     Emma Woodward  21     Gareth Evans  22     Helen Hanson  23     Conceição Egas  24     M. Isabel Tejada et al.  25     Nicoline Hoogerbrugge  25     Marc Tischkowitz  26     Carla Oliveira  27     José García Peláez  27     Patrick R. Benusiglio  27     Laura Gieldon & Evelyn Schrock  28     Elke Holinski-Feder & Verena Steinke  29     Daniele Calistri & Gianluca Tedaldi  30     Catarina Silveira & Inês Silva  31     Mateja Krajc, Ana Blatnik & Srdjan Novacovik  32     Jose Soto  33     Kristina Lagerstedt-Robinson & Svetlana Bajali Lagercrantz  34     Karim Dahan & Damien Feret  35    
1 i3s, Porto, Portugal
2 IPATIMUP, Porto/PT, Porto, Portugal
3 Centro Hospitalar Universitário São João (CHUSJ), Porto, Portugal
4 IPO, Instituto Português de Oncologia do Porto, Porto, Portugal
5 University of Leuven, Leuven, Belgium
6 Laboratory of Human Genetics, GIGA-Institute, Liège, Belgium
7 University Hospital of Ghent, Ghent, Belgium
8 Institut Curie, Paris, France
9 GH Pitié- Salpêtrière, Paris, France
10 University Hospital Bonn, Bonn, Germany
11 University of Bonn, Bonn, Germany
12 University of Pavia, Pavia, Italy
13 Institute of Genomic Medicine, Catholic University of the Sacred Heart, Rome, Italy
14 University Clinic of Navarra, Pamplona, Spain
15 Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Barcelona, Spain
16 Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL) and Biomedical Research Institute (IDIBGI), Barcelona-Girona, Spain
17 Hospital Vall d’Hebron and Universitat Autonoma de Barcelona, Barcelona, Spain
18 Molecular Diagnostics Laboratory, Fundación Rioja Salud, Logroño, Spain
19 Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
20 MRC Cancer Unit, Hutchison-MRC Research Centre, Cambridge, United Kingdom
21 University of Manchester, Manchester, United Kingdom
22 Manchester Centre for Genomic Medicine, Manchester, United Kingdom
23 St Georges NHS Foundation Trust, London, United Kingdom
24 Biocant- Transfer Technology Association, Cantanhede, Portugal
25 Biocruces Health Research Institute, Barakaldo, Spain
26 University of Cambridge, Cambridge, United Kingdom
27 Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
28 TU Dresden, Medical Faculty CGC, Dresden, Germany
29 Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
30 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
31 Genomed Diagnósticos de Medicina Molecular, S.A., Lisbon, Portugal
32 Institute of Oncology Ljubljana, Ljubljana, Slovenia
33 Elche University Hospital, Elche, Spain
34 Karolinska Institutet, Stockholm, Sweden
35 Institut de Pathologie et de Génétique, Gosselies, Belgium

Topic
Digestive Oncology, Disease Mechanisms, Histopathology

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing